Roche announced a definitive agreement to acquire 89bio for up to $3.5 billion, including upfront cash of $2.4 billion and milestone payments. 89bio's lead asset, pegozafermin, is an FGF21 analog in Phase III development for moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The acquisition strengthens Roche’s cardiovascular and metabolic disease portfolio and aligns with its strategic investment in therapies addressing fatty liver disease. Analysts foresee peak annual sales of pegozafermin exceeding $2 billion, highlighting its commercial potential.